Skip to main content

Research on cystic fibrosis in Belgium

Recherche sur la mucoviscidose en Belgique
Cystic fibrosis is the most common fatal genetic disease in western countries ©jolopes-Fotolia

Cystic fibrosis is the most common fatal genetic disease in western countries. It affects one out of every 2,500 births and patients have a 35-year life expectancy. There is currently no cure for cystic fibrosis. The Air Liquide Foundation supports research carried out by the Université Libre de Bruxelles in order to fight this disease.

A new hope for treatment
A novel class of antibodies known as nanobodies has been discovered, offering hope for treating cystic fibrosis. These nanobodies are smaller than traditional antibodies. The project examining this new approach is led by the Université Libre de Bruxelles with support from the Air Liquide Foundation.

More about this project

The Air Liquide Foundation team

Bruno Leprince-Ringuet

Bruno Leprince-Ringuet

General Manager

Natcha Brunet, Chargée de mécénat

Natacha Brunet

Philanthropy coordinator

© Clemence Bruneton

Clémence Bruneton

Communications Officer

Geneviève Capbern-Gasqueton, Attachée de mécénat

Geneviève Capbern-Gasqueton

Philanthropy coordinator

Get in touch

By mail
Fondation Air Liquide 
75 Quai d'Orsay
75007 PARIS
FRANCE

Send us an email

You have a project?